

2009 March

Hybrigenics' positive meeting with FDA on US clinical development of inecalcitol Successful pre-IND meeting with the FDA sets the stage for the development of inecalcitol for prostate cancer in the United States. Paris, March 12, 2009 - Hybrigenics announced today the comprehensive review by the American Food and Drug Administration of the pharmaceutical, preclinical and clinical information on inecalcitol. A proposal for a two-step efficacy development plan for hormone-refractory prostate cancer in combination with Taxotere® has been accepted.